Abstract 203P
Background
Esophageal squamous cell carcinoma (ESCC) is the main subtype of esophageal cancer in China. We conducted a prospective clinical trial of preoperative Durvalumab combined chemotherapy in patients with locally advanced ESCC.
Methods
Clinical resectable IIB-IVA ESCC patients were enrolled in the study. Patient received neoadjuvant Durvalumab 750mg combined chemotherapy (docetaxel 75mg/m2 plus cisplatin 75mg/m2 or carboplatin area under curve 4-5) every 3 weeks for 4 cycles before surgery. The primary endpoint was the pathological complete response rate (pCR) and the radical resection rate (R0).
Results
26 eligible patients were enrolled in the study and all completed four cycles of neoadjuvant therapy. The objective response rate is 80.8%, and the disease control rate was 100%. Among the 22 resectable tumor patients, 20 received McKeown MIE, and the other 2 patients who achieved response (1 PR and 1 CR) refused surgery due to concerns about complications. 20 patients underwent esophagectomy within 33-60 days (median 47 days) after neoadjuvant therapy, and 19 patients underwent radical resection with a R0 resection rate of 95%. pCR (ypT0N0) was observed in 3 patients (15.8%). 2 patients (10.5%) achieved complete remission of the primary tumor (ypT0N1). 1 patient (5.3%) had an American Society of Pathologists (CAP) score of 1, 7 patients (36.8%) had a CAP score of 2, and 8 patients (6/19, 31.6%) had a CAP score of 3. Most treatment-related AEs (TRAEs) were grade 1 or 2. 8 cases (30.8%), 13 cases (50%), and 1 case (3.8%) developed leukopenia, decreased neutrophil count, and dermatitis, respectively ¾ Level TRAE. In terms of surgical complications, 2 patients had anastomotic leakage (10%), and 1 patient had recurrent laryngeal nerve injury (5%).
Conclusions
The combination of neoadjuvant Durvalumab chemotherapy has achieved satisfactory initial efficacy and safety results in locally advanced ESCC. Neoadjuvant immunotherapy does not increase perioperative complications and can achieve higher pathological remission rates, which may lead to better PFS and OS in the future. This study is currently the first clinical trial to use PD-L1 inhibitors in the treatment of esophageal squamous cell carcinoma.
Clinical trial identification
NCT04568200.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract